The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours
J Jernman, MJ Välimäki, J Louhimo, C Haglund… - …, 2012 - karger.com
Abstract Background: Approximately 10–15% of gastroenteropancreatic neuroendocrine
tumours (NETs, carcinoids) occur in the rectum, some of which are potentially able to …
tumours (NETs, carcinoids) occur in the rectum, some of which are potentially able to …
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
M Carpelan-Holmström, J Louhimo… - Anticancer …, 2002 - europepmc.org
Background CEA, CA 19-9, CA 242 and CA 72-4 are commonly used tumour markers for
gastrointestinal malignancies. The advantage of the concomitant use of these markers is …
gastrointestinal malignancies. The advantage of the concomitant use of these markers is …
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers
CM Sturgeon, MJ Duffy, BR Hofmann… - Clinical …, 2010 - academic.oup.com
Abstract Background: Updated National Academy of Clinical Biochemistry Laboratory
Medicine Practice Guidelines for the use of tumor markers in the clinic have been …
Medicine Practice Guidelines for the use of tumor markers in the clinic have been …
Serum HCGβ, CA 72‐4 and CEA are independent prognostic factors in colorectal cancer
J Louhimo, M Carpelan‐Holmström… - … journal of cancer, 2002 - Wiley Online Library
In colorectal cancer, stage is considered to be the strongest prognostic factor, but also serum
tumour markers have been reported to be of prognostic value. The aim of our study was to …
tumour markers have been reported to be of prognostic value. The aim of our study was to …
[HTML][HTML] Necroptosis is an important severity determinant and potential therapeutic target in experimental severe pancreatitis
JM Louhimo, ML Steer, G Perides - Cellular and molecular …, 2016 - Elsevier
Background & Aims Severe acute pancreatitis is characterized by acinar cell death and
inflammation. Necroptosis is an aggressive and proinflammatory mode of cell death that can …
inflammation. Necroptosis is an aggressive and proinflammatory mode of cell death that can …
Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients
P Siironen, J Louhimo, S Nordling, A Ristimäki… - Tumor Biology, 2005 - karger.com
Background: Although papillary thyroid cancer (PTC) is among the most curable cancer
types, it can be a distressing disease for those patients suffering from frequent recurrences …
types, it can be a distressing disease for those patients suffering from frequent recurrences …
CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the diagnosis of recurrent colorectal cancer
M Carpelan-Holmström, J Louhimo, UH Stenman… - Tumor biology, 2004 - karger.com
Objective: The purpose of this study was to compare the utility of serum CEA, CA 19-9, CA
242, CA 72-4 and human chorionic gonadotropin (hCG) β in the follow-up of 102 surgically …
242, CA 72-4 and human chorionic gonadotropin (hCG) β in the follow-up of 102 surgically …
Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer
C Kersten, J Louhimo, A Ålgars, A Lahdesmaki… - Acta …, 2013 - Taylor & Francis
Background. To characterize the stage-specific prognostic relevance of preoperative
systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) …
systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) …
Syndecan-1 expression–a novel prognostic marker in pancreatic cancer
Objective: Syndecan-1 is a transmembrane receptor that participates in cell-cell and cell-
matrix interactions, cell proliferation and cell migration. Expression of syndecan-1 is …
matrix interactions, cell proliferation and cell migration. Expression of syndecan-1 is …
Serum HCGβ and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer
J Louhimo, H Alfthan, UH Stenman, C Haglund - Oncology, 2004 - karger.com
Objective: In pancreatic cancer, the extent of the spread of the disease is considered to be
the strongest prognostic factor. In addition, tumor markers, particularly CA 19-9, may also …
the strongest prognostic factor. In addition, tumor markers, particularly CA 19-9, may also …